Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22459876 | 0.95 | EGFR (0.39) | RARBPTPN11CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL22459837 | 0.92 | POLB (0.41) | RARBPPARGPTPN11 | |
| SCHEMBL22459276 | 0.89 | EGFR (0.41) | RARBPPARGCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL22459808 | 0.89 | TNKS2 (0.42) | PPARGPPARATNKS2MET | |
| SCHEMBL22459240 | 0.85 | TNKS2 (0.41) | PPARGPPARATNKS2MET | |
| SCHEMBL19855659 | 0.85 | PTPN11 (0.39) | RARBPTPN11CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL22083053 | 0.85 | PTPN11 (0.43) | RARBPPARGPPARAPTPN11AGTR2 | |
| SCHEMBL22459369 | 0.85 | RARB (0.35) | RARBPPARGAGTR2TNKS2MET | |
| SCHEMBL22459568 | 0.84 | PPARG (0.39) | PPARGPTPN11CYP11B1CYP11B2TNKS2 | |
| SCHEMBL22459277 | 0.84 | EGFR (0.37) | RARBTNKS2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, CCND1, CPNE4 | RARB 3668/4885PPARG 4176/4885PPARA 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.